Imaging Center COE

CONDOR: Study of 18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer - Michael J. Morris

Details
Michael Morris Oliver Sartor and Alicia Morgans discuss the CONDOR study, the second of two prospective clinical trials designed in collaboration with the FDA to demonstrate the diagnostic performance of PyL in patients with biochemically recurrent prostate cancer. Correct localization rate (CLR), or the positive predictive value of the PyL scan, was established as the primary endpoint and the CLR...

Focal Therapy in Prostate Cancer - Art Rastinehad

Details
Prostate cancer survivor John Fortin is joined by Art Rastinehad a professor of urology and radiology at Mount Sinai to discuss targeted therapies for prostate cancer. Together they discuss when patients are recommended to active surveillance, versus when they must receive more complex treatment regimes. They discuss the research done to identify and test focal therapies for prostate cancer. Dr. R...

PSMA PET/CT Imaging for Staging High-risk Prostate Cancer Prior to Curative-intent Surgery or Radiotherapy (proPSMA) - Michael Hofman and Declan Murphy

Details
Declan Murphy and Michael Hofman join Alicia Morgans to discuss the results from proPSMA study "A prospective randomized multi-center study of the impact of Ga-68 PSMA-PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy." Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localized prostate canc...

PSMA PET Diagnostic Imaging in the Current Era - Jeremie Calais

Details
Phillip Koo interviews Jeremie Calais about PSMA PET imaging in patients with localized prostate cancer. Professor Calais discusses the advantages of whole-body PSMA PET imaging in patients with presumed localized cancer, as well as those likely to have extraprostatic disease. The PSMA whole-body imaging modality can be used to identify cancer lesions with high sensitivity in patients. PSMA PET is...

Imaging and Flare Responses When Assessing Patients with Metastatic Castration-Resistant Prostate Cancer - Anwar Padhani

Details
Anwar Padhani discusses his presentation from the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) on the flare phenomenon in advanced prostate cancer. Because of this phenomenon, clinicians have created workarounds. Dr. Padhani expands that there are multiple consequences of the workarounds, one being that they cause delays in the treatment schedule. Precision oncology trials require ra...

Initial Experience with Actinium- 225 PSMA in Advanced Prostate Cancer - Machaba Michael Sathekge

Details
Mike Machaba Sathekge, MD, PhD presents on the power of medicine, specifically targeted radionuclide therapies and the use of actinium-225 in advanced prostate cancer. Targeted α-therapy with 225Ac-PSMA-617 although still preliminary, has demonstrated strong potential to significantly benefit advanced-stage prostate cancer patients. He discusses the initial experience with 225Ac-PSMA-617 in a deve...

Advances in PSMA-directed Radionuclide Therapy - Howard Soule

Details
Howard Soule discusses highlights and his takeaways from the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Soule highlights the importance of coming to these conferences to understand where the gaps are in the treatment landscape and the benefit of these global conferences for clinicians from resource-limited countries. They continue on to discuss imaging, PSMA, and the VISION tr...

The Use of Novel Imaging Methods in Prostate Cancer - Stefano Fanti

Details
Stefano Fanti joins Phillip Koo at the 2019 European Associate of Urology to discuss the use of novel imaging methods in the prostate cancer space. Their discussion highlights the excitement and limitations around imaging including the methods of MRI and PET, and its impacts on patient care. Biographies: Stefano Fanti, Professor Department of Experimental, Diagnostic and Specialty Medicine - DIMES...

Insights on Nuclear Imaging for Prostate Cancer- Stefano Fanti

Details
Stefano Fanti reviews the consensus paper on nuclear imaging for prostate cancer which was recently published in Lancet Oncology in December 2018. PSMA PET should be offered early in biochemical recurrence as it is the most sensitive and the EAU has incorporated PSMA PET into their guidelines as well, recommending PSMA PET for PSA >0.2. Stefano and Alicia discuss the various PSMA technologies and...

Incorporate Next Generation Imaging Tools Into Clinical Practice - Piet Ost

Details
Piet Ost shares details of his recent presentation focusing on biochemical recurrent prostate cancer, specifically in the recurrent setting, and answering the question such as should we be investing in this novel imaging for all patients or should we dial back a bit and only have that for selected patients? Who should get this imaging?. He expressed his intent to try to convince people to think be...